Fentanyl
- Generic Name
- Fentanyl
- Brand Names
- Abstral, Actiq, Duragesic, Effentora, Fentora, Instanyl, Lazanda, Sublimaze, Subsys, PecFent
- Drug Type
- Small Molecule
- Chemical Formula
- C22H28N2O
- CAS Number
- 437-38-7
- Unique Ingredient Identifier
- UF599785JZ
- Background
Fentanyl, a potent opioid agonist, was developed in the 1950s to fill a need for strong and rapid analgesia. Because of these characteristics, fentanyl is commonly used to treat chronic cancer pain or in anesthesia. Fentanyl is related to other opioids like morphine and oxycodone.
Fentanyl's high potency has also made it a common adulterant in illicit drugs, especially heroin. In 2017, 47600 overdose deaths in the United States involved some opioid (over 2/3 of all overdose deaths). Opioid overdoses kill an average of 11 Canadians daily.
Fentanyl was FDA approved in 1968.
- Indication
Fentanyl intravenous or intramuscular injections are indicated for short term analgesia during induction, maintenance, and recovery from general or regional anesthesia. These injections are also used with a neuroleptic for premedication, induction, and as an adjunct to maintenance of anesthesia. Finally, fentanyl intravenous or intramuscular injections are used with oxygen for anesthesia in high risk patients.
Fentanyl sublingual tablets, transmucosal lozenges, buccal tablets, sublingual sprays, transdermal systems, and nasal sprays are indicated for the management of breakthrough pain in opioid tolerant cancer patients who require around the clock pain management.
- Associated Conditions
- Cancer Related Pain (Breakthrough Pain), Severe, Chronic Pain
- Associated Therapies
- Anesthetic premedication therapy, Anesthetics Agent, General Anesthesia, Induction of anesthesia therapy, Maintenance of anesthesia therapy, Regional Anesthesia therapy
A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, Compared With Placebo in Patients With Osteoarthritis
- Conditions
- OsteoarthritisArthritis
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 418
- Registration Number
- NCT00236366
Evaluation of the Efficacy and Safety of Fentanyl Delivered by Adhesive Skin Patch in Out-Patients With Chronic Cancer Pain
- Conditions
- Pain
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen Cilag S.A.S.
- Target Recruit Count
- 34
- Registration Number
- NCT00236327
Phase II Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Cancer Pain- Assessment of Effectiveness, Safety and Pharmacokinetics -
- Conditions
- Pain, Intractable
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 87
- Registration Number
- NCT00216658
Phase III Clinical Trial of Fentanyl Transdermal Matrix Patch, in the Management of Chronic Intractable Pain- Assessment of Effectiveness, Safety and Pharmacokinetics
- Conditions
- Pain, Intractable
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-02-01
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 139
- Registration Number
- NCT00216684
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain
- Conditions
- Chronic Neuropathic Pain
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Target Recruit Count
- 120
- Registration Number
- NCT00214955
- Locations
- 🇺🇸
Vertex Clinical Research, Inc., Bakersfield, California, United States
🇺🇸Clinical Research of W Florida, Clearwater, Florida, United States
🇺🇸Center for Prospective Outcome, Marietta, Georgia, United States
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
- Conditions
- Chronic Low Back Pain
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Cephalon
- Registration Number
- NCT00214942
- Locations
- 🇺🇸
Mid America Physiatrists, PA, Overland Park, Kansas, United States
🇺🇸Clopton Clinic, Jonesboro, Arkansas, United States
🇺🇸Florida Institute of Medical R, Jacksonville, Florida, United States
Efficacy of Transdermal Fentanyl for Chronic Neuropathic Pain
- Conditions
- Peripheral NeuropathyComplex Regional Pain Syndromes (CRPS)
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 53
- Registration Number
- NCT00181246
Study of Fentanyl-Propofol-EMLA of L.M.X4 Technique for Bone Marrow Aspiration
- Conditions
- PainBone Marrow Disease
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 168
- Registration Number
- NCT00187135
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Pharmaco-Economic Study Of Ultiva In Intensive Care Unit(ICU)Subjects
- Conditions
- Sedation
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2008-10-16
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 224
- Registration Number
- NCT00158873
- Locations
- 🇳🇱
GSK Investigational Site, Zwolle, Netherlands
Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain
- First Posted Date
- 2005-08-04
- Last Posted Date
- 2012-06-05
- Lead Sponsor
- ZARS Pharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00126789
- Locations
- 🇺🇸
Loma Linda Center for Pain Management, Loma Linda, California, United States
🇺🇸The Center for Clinical Research, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.